PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
Thorsten DerlinSebastian SchmuckCathleen JuhlJohanna ZörgiebelSophie M SchneefeldAlmut C A WalteKatja HueperChristoph A von KlotChristoph HenkenberensHans ChristiansenJames T ThackerayTobias L RossFrank M BengelPublished in: European journal of nuclear medicine and molecular imaging (2018)
In this study, [68Ga]THP-PSMA PET/CT showed suitable detection rates in patients with biochemical recurrence of prostate cancer and PSA levels ≥ 2 ng /mL. Detections rates were lower than in previous studies evaluating other PSMA ligands, though prospective direct radiotracer comparison studies are mandatory particularly in patients with low PSA levels to evaluate the relative performance of different PSMA ligands.